ISPOR Europe is returning to Barcelona this year and Broadstreet is pleased to be there with six studies to present on subjects ranging from patient preferences for early oncology trial endpoints to a systematic review of loss of ambulation in limb-girdle muscular dystrophy. Additionally, Broadstreet’s Shelagh Szabo will be participating in a panel on accounting for variation in patient preferences in health technology assessment.
Shelagh will be taking part in the issue panel Should We Account for Variation in Patient Preferences in Health Technology Assessment? Individual Preferences With Respect to the Characteristics and Possible Outcomes of a Healthcare Intervention May Vary. The panel will take place on Monday, the 18th at 10:15. The session should be interesting and if you are at ISPOR we encourage you to attend.
Supporting the theme of this session, Shelagh along with colleagues Neil Hawkins and Evi Germeni from University of Glasgow are also presenting a poster on their ongoing qualitative study about how patient treatment preferences are shaped and the mechanisms underlying them. The findings of this study, which involved an exploration of real-world preference heterogeneity subgroups among those with psoriasis, may ideally be useful for facilitating discussions between patients with psoriasis and their physicians; and help to improve study design and technology assessment. We will also be presenting posters for a couple of our other in-house research projects looking at trends and insights in evidence generation for health technology assessment submissions.
Another of our patient focused projects will be featured in a mini presentation at the conference. In this investigation, a qualitative patient preference study, Canadians with early-stage lung, liver, and breast cancer shared their views on early oncology trial endpoints. The study highlights how endpoints like recurrence-free, disease-free, and event-free survival align with patients’ treatment goals beyond simple survival and reinforce the value of these endpoints in supporting the rapid approval of effective treatments.
We invite you to check out all our posters:
In Poster Session 1 on Monday, November 18th (10:30 a.m. – 1:30 p.m.):
PCR29: EQ-5D Utility According to Patient Self-Reported Health on the Visual Analogue Scale (VAS) in Duchenne Muscular Dystrophy (DMD)
Authors: Filipovic Audhya I1, Szabo SM2, Griffin EC2, Feeny D3, Malone D4, Neumann P5, Iannaccone ST6, Jayasinghe P2, Gooch KL1
1Sarepta Therapeutics, Inc., Cambridge, MA, USA, 2Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada, 3McMaster University, Hamilton, ON, Canada, 4University of Utah College of Pharmacy, Salt Lake City, UT, USA, 5Tufts University School of Medicine, Boston, MA, USA, 6The University of Texas Southwestern, Dallas, TX, USA
In Poster Session 2 on Monday, November 18th (4:00 p.m. – 7:00 p.m.):
PT18: Preferences for and Importance of Early Oncology Trial Endpoints to Canadians With Early-Stage Cancer: An Interim Analysis of a Qualitative Patient Preference Study
Authors: Szabo SM1, Walker SE1, Griffin EC1, Ting E2, Simbulan F2, McMillan A3, Bick R4, Snow S5
1Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada, 2AstraZeneca Canada, Mississauga, ON, Canada, 3Rethink Breast Cancer, Toronto, ON, Canada, 4CanCertainty, Markham, ON, Canada, 5Dalhousie University, Halifax, NS, Canada
SA33: Use of Novel Population-Adjusted Indirect Comparisons in Recent Submissions to the National Institute for Health and Care Excellence (NICE)
Authors: Lozano-Ortega G, Besada M
Broadstreet HEOR, Vancouver, BC, Canada
In Poster Session 4 on Tuesday, November 19th (4:00 p.m. – 7:00 p.m.):
CO158: Loss of Ambulation (LOA) in Patients With Limb-Girdle Muscular Dystrophy (LGMD) Sarcoglycanopathy Subtypes: A Systematic Review
Authors: Cheung A1, Murty S2, Müller-York A2, Sudharshan L2, Tinajero MG1, Szabo SM1
1Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada, 2Sarepta Therapeutics, Cambridge, MA, USA
PCR251: Understanding Heterogeneity in Patient Preferences for Psoriasis Treatments: A Qualitative Grounded Theory Study
Authors: Szabo SM, Hawkins N, Germeni E
University of Glasgow, Glasgow, UK
In Poster Session 5 on Wednesday, November 20th (9:00 a.m. – 11:30 a.m.):
HTA370: Patient Voice in Rare Disease Health Technology Assessments (HTA): Recent Trends in the Use of Qualitative Research
Authors; Powell LC, Dunne J, Griffin EC, Martin M, Szabo SM
Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada
If you have questions about any of these projects or how Broadstreet can support the development of your HEOR projects, please get in touch at info@broadstreetheor.com.
